lopinavir + ritonavir + efavirenz + artemether + lumefantrine

This is a five-drug combination consisting of three antiretroviral agents—lopinavir, ritonavir, and efavirenz—and two antimalarial agents—artemether and lumefantrine. Lopinavir and ritonavir are protease inhibitors used in the treatment of HIV infection; ritonavir also acts as a pharmacokinetic enhancer by inhibiting CYP3A4-mediated metabolism of lopinavir, thereby increasing its plasma concentration. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV-1 reverse transcriptase activity. Artemether and lumefantrine are combined as an artemisinin-based combination therapy (ACT) for the treatment of uncomplicated malaria caused by Plasmodium falciparum; artemether provides rapid parasite clearance while lumefantrine eliminates residual parasites to prevent recrudescence[1][2][6][7]. This specific five-drug combination does not correspond to any single marketed product or fixed-dose formulation but may be used in clinical settings where co-infection with HIV and malaria requires simultaneous management.